Sudarshan Pharma promoters pledge 1.33 crore shares to Satin Finserv

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Hemal V Mehta and Sachin V Mehta each pledged 66.50 lakh shares
  • Encumbrance created in favor of Satin Finserv Limited on August 25, 2026
  • Reason cited as security for loans taken by third parties
  • Total encumbered holding for both promoters rises to 5.21%
  • Disclosures filed under SEBI SAST Regulations 31(1) and 31(2)
powered bylight_fuzz_icon
49302141

*this image is generated using AI for illustrative purposes only.

Sudarshan Pharma Industries promoters Hemal V Mehta and Sachin V Mehta pledged a combined 1.33 crore equity shares on August 25, 2026. The encumbrance was created in favor of Satin Finserv Limited as security for loans taken by third parties.

Pledge Details

Both promoters disclosed the creation of pledges under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosures were filed with BSE Limited on August 26, 2026.

Promoter Shares Pledged % of Capital Pre-existing Encumbered Shares Total Encumbered Post-Event
Hemal V Mehta 66,50,000 2.61% 66,00,000 1,32,50,000 (5.21%)
Sachin V Mehta 66,50,000 2.61% 66,00,000 1,32,50,000 (5.21%)

Hemal V Mehta holds 6,85,21,020 shares, representing 26.93% of the total share capital. Sachin V Mehta holds 7,07,05,470 shares, accounting for 27.79% of the total share capital.

What the Numbers Show

The new pledge increases the total encumbered stake for both promoters to 5.21% of the company’s total share capital. This indicates that roughly one-fifth of each promoter’s individual holding is now pledged, as Hemal V Mehta’s encumbered portion rises from 2.59% to 5.21%, and Sachin V Mehta’s follows the identical trajectory.

Historical Stock Returns for Sudarshan Pharma Industries

1 Day5 Days1 Month6 Months1 Year5 Years
+0.85%+4.85%-2.85%+43.44%+15.66%0.0%

How might the increased pledge ratio of 5.21% impact Sudarshan Pharma's credit rating or future borrowing capacity?

Given that the loans are for third parties, what are the potential risks to the promoters' control if those third-party obligations default?

Will this additional encumbrance influence institutional investors' confidence in the company's corporate governance and promoter stability?

Sudarshan Pharma Industries
View Company Insights
View All News
like20
dislike

Sudarshan Pharma promoters pledge 6.6 lakh shares each for loan security

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Hemal V Mehta and Sachin V Mehta pledged 6,60,000 shares each
  • Total stake encumbered is 2.64% per promoter
  • Shares pledged to Satin Finserv Limited as loan security
  • No prior encumbrances existed on these holdings
powered bylight_fuzz_icon
48919687

*this image is generated using AI for illustrative purposes only.

Sudarshan Pharma Industries promoters Hemal V Mehta and Sachin V Mehta created a pledge on 6,60,000 equity shares each on August 20, 2026. The encumbrance serves as security for loans taken by the company.

The pledge covers 2.64% of the total share capital for each promoter. Satin Finserv Limited is the entity in whose favor the shares were encumbered.

Pledge Details

Both promoters reported no prior encumbrances on their holdings before this transaction. The creation of these pledges was disclosed to BSE Limited on August 21, 2026, in compliance with Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Promoter Shares Pledged Stake Encumbered Lender
Hemal V Mehta 6,60,000 2.64% Satin Finserv Limited
Sachin V Mehta 6,60,000 2.64% Satin Finserv Limited

Hemal V Mehta holds 6,85,21,020 shares (27.44%), while Sachin V Mehta holds 7,07,05,470 shares (28.32%). The post-event holding of encumbered shares stands at 6,60,000 for both individuals.

Historical Stock Returns for Sudarshan Pharma Industries

1 Day5 Days1 Month6 Months1 Year5 Years
+0.85%+4.85%-2.85%+43.44%+15.66%0.0%

What is the primary purpose of the loans secured by these pledges, and will the funds be used for corporate expansion or personal liquidity needs?

How might this pledge activity impact Sudarshan Pharma's credit rating or future borrowing costs from financial institutions?

Given that Satin Finserv is the lender, what are the specific covenants or margin call triggers associated with this encumbrance?

Sudarshan Pharma Industries
View Company Insights
View All News
like15
dislike

More News on Sudarshan Pharma Industries

1 Year Returns:+15.66%